PDT Partners LLC Invests $1.20 Million in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

PDT Partners LLC bought a new position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 147,162 shares of the company's stock, valued at approximately $1,199,000. PDT Partners LLC owned about 0.26% of Ginkgo Bioworks as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of DNA. Verition Fund Management LLC acquired a new position in Ginkgo Bioworks during the third quarter worth approximately $792,000. BNP Paribas Financial Markets acquired a new position in Ginkgo Bioworks in the third quarter valued at $1,287,000. Forbes J M & Co. LLP purchased a new stake in Ginkgo Bioworks during the third quarter valued at about $1,019,000. PFG Investments LLC acquired a new stake in Ginkgo Bioworks during the third quarter worth about $1,541,000. Finally, Wellington Wealth Strategies LLC. purchased a new position in shares of Ginkgo Bioworks in the 2nd quarter worth about $41,000. Institutional investors and hedge funds own 78.63% of the company's stock.

Ginkgo Bioworks Stock Up 10.5 %

Shares of DNA stock traded up $0.92 during trading hours on Monday, reaching $9.62. The company had a trading volume of 1,501,314 shares, compared to its average volume of 1,146,575. The stock has a market capitalization of $552.66 million, a P/E ratio of -0.74 and a beta of 1.09. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.26 and a twelve month high of $75.20. The company's fifty day simple moving average is $7.97.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on DNA. TD Cowen boosted their target price on Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a report on Friday, September 20th. BTIG Research boosted their price objective on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a research note on Friday, August 23rd. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Ginkgo Bioworks has an average rating of "Hold" and an average price target of $4.58.

About Ginkgo Bioworks

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.